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Abstract 
Introduction: For safe and effective neonatal antibiotic therapy, knowledge of the pharmacokinetic 
parameters of antibacterial agents in neonates is a prerequisite. Fast maturational changes during 
the neonatal period influence pharmacokinetic and pharmacodynamic parameters and their 
variability. Consequently, the need for applying quantitative clinical pharmacology and determining 
optimal drug dosing regimens in neonates has become increasingly recognized.  
Areas covered: Modern quantitative approaches, such as pharmacometrics, are increasingly utilized 
to characterize, understand and predict the pharmacokinetics of a drug and its effect, and to quantify 
the variability in the neonatal population. Individual factors, called covariates in modeling, are 
integrated in such approaches to explain inter-individual pharmacokinetic variability. 
Pharmacometrics has been shown to be a relevant tool to evaluate, optimize and individualize drug 
dosing regimens.  
Expert opinion: Challenges for optimal use of antibiotics in neonates can largely be overcome with 
quantitative clinical pharmacology practice. Clinicians should be aware that there is a next step to 
support the clinical decision-making based on clinical characteristics and therapeutic drug 
monitoring, through Bayesian-based modeling and simulation methods. Pharmacometric modeling 
and simulation approaches permit us to characterize population average, inter-subject and intra-
subject variability of pharmacokinetic parameters such as clearance and volume of distribution, and 
to identify and quantify key factors that influence the pharmacokinetic behavior of antibiotics during 
the neonatal period. 
Keywords: Antibiotics, clinical pharmacology, modeling and simulation, neonate, pharmacometrics, 
therapeutic drug monitoring 
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Article highlights box 
• Low plasma protein binding, changes in body compartments and kidney function influence 
pharmacokinetic (PK) behavior of antibiotics in neonates.  
• Quantitative PK approaches, including pharmacometric modeling and simulation, tailored to 
neonates are needed to further enhance understanding of PK behavior of antibiotics in 
neonates. 
• Pharmacometric models can integrate the time course of dose-concentration relationships, 
identify sources of PK variability, and provide a scientific basis for optimizing dosing of 
antibiotic agents in neonates.  
• In conjunction with quantitative pharmacology approaches and appropriate clinical 
interpretation, therapeutic drug monitoring (TDM) is a valuable tool in neonatal intensive 
care units. 
• Advanced TDM practice leverages Bayesian modeling and simulation methods to ensure safe 
and effective antibiotic therapy in neonates based on 4 components: (i) measured drug 
concentrations, (ii) developed population PK models with quantified variability in key PK 
parameters such as clearance and volume of distribution, (ii) identified time-dependent 
factors that influence key PK parameters during the first weeks of life, and (iv) characterized 
PD behavior and target levels of antibiotics in neonates. 
 
 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
2:2
0 2
8 J
an
ua
ry
 20
16
 
1. Introduction 
 
Pharmacokinetics (PK) describes the concentration time profiles of drugs in the body, and includes 
the processes of absorption, distribution, metabolism and excretion (ADME). The PK profile of drugs 
in neonates cannot be simply extrapolated from data obtained in older infants, children and adults, 
since major changes in the physiological characteristics that influence these PK processes happen in 
early infancy. Furthermore, these developmental changes in ADME do not show the same pattern of 
maturation [1,2]. 
Neonates are the group of children from birth up to and including the age of 27 days or the 
equivalent maturational age (44 weeks postmenstrual age) and include both preterm (< 37 weeks of 
gestational age) and term neonates [3]. For safe and effective neonatal antibiotic therapy, knowledge 
of the pharmacokinetic parameters of antibacterial agents in neonates is a prerequisite. Antibiotics 
are the class of medicines most frequently prescribed in neonates due to the high morbidity and 
mortality of infectious diseases in preterm and term neonates. Early antibiotic therapy and effective 
dosing are essential to provide optimal response and limit the spread of resistance [4]. However, fast 
maturational changes during the neonatal period result in very extensive PK variability, but also 
affect pharmacodynamics (PD) and may result in differences in drug efficacy, potency and/or toxicity. 
Across pediatric life, organ size and function change as does body composition, physiology, and 
cellular function. There is an initial decrease (6-12 %) in birth weight, with a subsequent increase of 
50 % in the first 6 weeks of postnatal life. Moreover, weight doubles in the first 3-4 months to result 
in a 3 fold higher weight at the end of infancy. These physiological trends are further affected by 
either pharmacotherapy used or pathophysiological processes or co-morbidities [5]. Consequently, 
the need for adequate PK/PD studies, prospective validation of quantitative clinical pharmacology 
approaches in neonates, and determining the correct drug dosing regimen has become increasingly 
recognized.  Quantitative approaches, such as pharmacometrics, can be applied to optimize 
utilization and fine-tune of antibiotic dosing in neonates. A population approach, based on random 
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and limited sampling strategies, has not only improved the feasibility of these studies but has also 
significantly reduced the burden of classical PK studies.  
 
1.1. Characteristics of neonatal infections 
Neonatal sepsis is one of the major causes of morbidity and mortality in neonates, especially in low 
income countries [6]. The risk of sepsis for preterm neonates with a birth-weight between 1000 and 
1500 g in developed countries is 10%, which is around tenfold higher compared to term newborns 
[7,8]. The diagnosis of sepsis is based on both clinical symptoms as well as laboratory findings. Early-
onset infections occur during the first 72 hours of life and are caused by vertical transmission of 
bacterial pathogens, acquired from the maternal genital tract in utero or during delivery, while late-
onset infections, after 3 days of life, include those pathogens acquired from the maternal genital 
tract as well as after birth through human contact, contaminated equipment or materials, i.e. 
horizontal transmission [9]. The incidence of documented early-onset neonatal sepsis varies between 
0.5 and 1% of all deliveries, and late-onset sepsis is seen in more than 25% of very low birth weight 
infants treated in neonatal intensive care units (NICUs) [10,11].  Escherichia coli and Streptococcus 
Agalactiae are still the two most important causes of early-onset infections, while methicillin 
resistant coagulase negative staphylococci are the most common organisms involved in the late-
onset ones [12].  
The high incidence of infections in neonates, the immaturity of the immune system, and the subtle 
and nonspecific clinical signs and symptoms of infection explain the frequent use of antibiotics in 
neonates. Due to high morbidity and mortality in this age group, the threshold to initiate antibiotic 
therapy is low and empirical treatment is usually started while awaiting blood culture results and 
sensitivity tests. As soon as the results of these tests become available, the initial treatment will be 
adjusted to a more targeted therapy for that specific pathogen or rapidly stopped when the infection 
is excluded.  
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1.2. Pharmacokinetic principles of antibiotic use in neonates 
The PK profile of a drug describes its absorption, distribution, metabolism and elimination. This 
general principle also applies to antibacterial agents, whereby the drug distribution and elimination 
are considered as main contributors to their PK specific properties in neonates. Absorption refers to 
the transfer of drugs from the site of administration into the systemic circulation. There are several 
routes of administration with a different bioavailability, and intravenous administration is 
recommended for the treatment in neonates to ensure 100% bioavailability [13]. However, there are 
additional complicating factors that are specific to intravenous drug administration, such as highly 
concentrated formulations in the currently available vials. As a consequence, necessary dilution, 
dosing inaccuracy or errors are more likely to occur in these fragile patients [14]. The more recent 
introduction of specific pediatric vials showed a reduced variability and improved dosing precision 
[15]. After absorption, the drug is distributed from the circulation into different bodily fluids, organs 
and tissues. The distribution of antibiotics in the body is mostly influenced by body composition, but 
also drug binding to plasma proteins, systemic and regional blood flow and permeability of 
membranes. Body composition changes with different gestational (GA) and postnatal ages (PNA). 
Total body water, expressed as a percentage of total body weight, is about 85% in preterm and 70% 
in term neonates, while total body fat in preterm is about 1% and 15% in term neonates, 
respectively. The high proportion of total body water and low proportion of fat tissue results in a 
lower volume of distribution (Vd) for lipophilic antibiotics like macrolides and fluoroquinolones, and 
a higher Vd for hydrophilic drugs like aminoglycosides, beta lactams and glycopeptides, as compared 
to adults. Furthermore, the peak plasma concentration of hydrophilic antibiotics will be delayed and 
blunted compared to older children or adults [16].  
It is well documented that plasma protein binding substantially affects tissue penetration, Vd and 
consequently, elimination half-life of antimicrobial agents. First, plasma protein binding reduces the 
unbound fraction of drug available for bacterial killing, since only the free drug can be distributed 
throughout the body and has a pharmacological effect. Second, high unbound fractions may result in 
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enhanced tissue distribution and an increased Vd of the drug. Finally, it should be taken into account 
that only the unbound fraction of drug is available for elimination from the vascular compartment 
[17]. Clinical implications of alterations in drug protein binding are most relevant for drugs which are 
highly protein bound and have a narrow therapeutic index [18]. The altered drug clearances may lead 
to significant variations of key PD parameters. Based on in vitro studies, the significant effect of 
proteins on bacterial killing was confirmed for beta lactams and fluoroquinolones. Zeitlinger et al. 
demonstrated that albumin substantially impaired the antimicrobial activity of ampicillin, oxacillin 
and moxifloxacin through a decrease in unbound drug concentration [19]. In neonates, there is 
reduced concentration of albumin and α-1 acid glycoprotein with a decreased drug protein-binding 
affinity as compared to children and adults. Consequently, the unbound proportion of highly protein-
bound drugs will increase. Smits et al. demonstrated that the unbound fraction of cefazolin in 
neonates was significantly higher than in adults, and it was partly dependent on albuminemia, but 
also on total drug concentration, indirect bilirubinemia and postmenstrual age [20]. Similar data 
were also found with flucloxacillin [21].  Therefore, the differences in unbound drug concentration 
should not solely be attributed to alterations in albumin concentrations, but these also depend on 
other patients’ clinical characteristics. Potentially altered PK of highly protein-bound antibacterial 
agents may be clinically relevant since they can influence PK parameters and the attainment of PD 
targets. For antibiotics with high binding affinity for proteins (> 70%), it is necessary to adjust the 
dose to maintain the drug concentrations in plasma close to the lower limit of the recommended 
therapeutic range. 
Maturation of drug metabolizing enzymes and kidney function will affect drug elimination in 
neonates. Rates of hepatic drug metabolism correspond with the low expression of drug 
metabolizing enzymes at birth, which gradually increases over time [22]. However, drug metabolism 
is likely only of limited relevance for antibiotics, except when metabolites interfere with therapeutic 
drug monitoring or metabolites have therapeutic effects [23]. The kidney elimination capacity is also 
influenced by physiological changes depending on age [24]. The majority of antibiotics used in the 
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neonatal population are excreted from the body by the kidneys, and kidney function is the main rate-
limiting step for their clearance. Kidney function includes glomerular filtration, tubular secretion and 
tubular reabsorption, whereby glomerular filtration seems to be more advanced than tubular 
function at birth. The glomerular filtration rate (GFR) in an individual newborn depends on both 
maturation until delivery (birth weight) and postnatal maturation (postnatal age). This pattern has 
been observed using either creatinine clearance estimates [25] or aminoglycoside clearance [26]. In 
the model proposed by De Cock et al., the developmental changes in clearance of antibiotics 
(gentamicin, tobramycin and vancomycin) from neonates to adults were considered to be system 
specific information and were characterized on the basis of one bodyweight-dependent exponent 
model [27]. Table 1.   
Term neonates have a rapid increase in GFR during the first 2 weeks of life and reach adult values by 
the first year of life, while premature infants show similar trends with a slower initial rise in GFR 
because nephrogenesis is not completed before 34 weeks of gestation [28,29]. Furthermore, 
exposure to drugs during the neonatal period might jeopardize the full development of the potential 
pool of glomeruli and that might have consequences later in life [30,31]. Interestingly, the postnatal 
maturation results in at least a twofold increase in GFR in the first weeks of life and is due to shifts in 
intra-renal blood flow [24].  In contrast, renal tubular drug transporters, such as the renal organic 
anion transporters, are also relevant in the phenotypic clearance of antibiotics (e.g. betalactams) 
excreted by the kidney [32,33]. The data regarding the maturation and expression of these 
transporters are currently limited. This necessitates the integration of the ontogeny related 
knowledge of the elimination route to predict drug specific, PK profiles in neonates. Modern, 
quantitative approaches, including pharmacometric modeling and model-based antibacterial 
therapy, provide a powerful research tool to integrate our knowledge into better and safer 
pharmacotherapy in neonates. Strategic applications of systems pharmacology and pharmacometrics 
have the great potential to streamline development and optimize utilization of drugs in pediatric 
patients, including neonates. 
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 2. Quantitative clinical pharmacology approaches to optimize use of 
antibiotics in neonates 
 
Dynamic maturation and developmental processes during the first weeks of life affect both drug 
exposure and response and their intra- and inter-subject variability in neonates. Quantitative 
approaches, such as pharmacometric modeling and simulation, are increasingly utilized to 
characterize such variability in drug exposure and response in order to individualize and optimize 
treatment strategies in this vulnerable patient population. 
2.1. Impact of covariates 
A key pharmacokinetic parameter, such as drug clearance, guides drug exposure and as a 
consequence antibiotic dosing strategies. For this reason, accurate determination of key parameters 
and their variability in the population of interest, e.g. neonates, is important. Drug clearance can be 
influenced by demographic, genetic, clinical or any other individual level factor, called covariates in 
modeling analyses. Pharmacometric covariate models represent mathematical parameterization 
between such factors and PK parameters and their variability. Based on principles of developmental 
pharmacology, pharmacometric covariate models should include key components reflecting 
developmental changes and underlying physiological processes that can affect key parameters such 
as clearance in neonates: (1) factors of size at birth and growth after birth, (2) factors of age-
dependent changes and maturational processes that can affect drug transporters and or drug 
metabolizing enzymes, and (3) factors that affect hepatic and/or kidney function. Body weight is 
widely used to describe size and growth. Age-dependent maturation can be characterized by various 
age descriptors, including post-menstrual age (PMA), gestational age (GA), post-natal age (PNA) or 
post-conceptional age (PCA) [34,35]. The incorporation of both GA and PNA in pharmacometric 
models is recommended to describe two different profiles accounting for ante-natal and post-natal 
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maturation processes. As a measure of kidney function serum or plasma creatinine level, creatinine 
clearance or glomerular filtration rate (GFR) based on measured creatinine, or cystatin C levels are 
used in the clinical setting [35,36,37,38]. Pharmacometric approaches can be utilized to characterize 
variability in drug exposure and response, and to identify and quantify covariates that influence key 
PK parameters and their variabilities. 
2.2. Pharmacometric modeling and simulation 
Pharmacometrics is an emerging science of developing and applying mathematical and statistical 
methods for characterizing, understanding, and predicting a drug’s PK, and its effects on biomarker 
and clinical responses over time [39,40,41]. Development of a model aims at translating biological 
knowledge into mathematical concepts to describe the general trend and variability in the observed 
data and subsequent predict the pattern in a new, but similar cohort [42]. 
For many years, PK of antibiotics has been analyzed with classical non-compartmental analysis (NCA), 
which does not assume any compartments. This simple approach is used to calculate PK parameters 
such as half-life or area under the serum concentration vs. time curve (AUC), which reflects total drug 
exposure. AUC is commonly calculated with a trapezoid rule approximating the AUC as a sum of 
several trapezoids. Such NCA PK analyses are highly dependent on PK sampling schedules and require 
consistent, rich PK sampling in all study subjects. On the other hand, pharmacometric PK models are 
built using compartments, representing kinetic concepts that do not necessarily represent any 
particular region of the body, linked to each other via rate constants. For each compartment, change 
in drug amounts over time is described by differential equations. Rate constant parameters can be 
transformed to provide more interpretable PK descriptors, such as drug clearance. There are several 
advantages of compartmental as compared to NCA analyses: (1) ability to predict drug concentration 
at any time, (2) flexibility in terms of timing and number of PK samples in study subjects, (3) 
quantification of covariate effects on key PK parameters, and (4) identification of sources of 
variability in drug exposure and response. Systems pharmacology models, including physiology-based 
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PK models (PBPK), may consist of a large number of compartments representing different organs or 
tissues in the human body [43,44]. Such PBPK models can provide a scientific rationale for first-time 
dosing in children and facilitate development of drugs in this population. However, further 
investigations are required and more data on maturational physiology in early infancy need to be 
collected to expand PBPK models to be used in clinical practice for antibiotics dosing in (pre)term 
neonates.  
Pharmacometric models have usually several components: structural, mathematical component (e.g. 
differential equations to mass balance between compartments), and statistical components, 
including those to evaluate and characterize covariate effects on key model parameters. Once 
structural and covariate components of models have been chosen, parameters and their variability 
can be estimated, applying the population approach and non-linear mixed-effects modeling [45]. 
Introduced by Sheiner et al, it is based on a simultaneous analysis of all data from a study population 
of interest while taking into account that different observations are derived from different 
individuals. Therefore, such an approach allows for sparse and random sampling designs, which are 
feasible and preferable in neonatal intensive care units (NICU). These kinds of population PK analyses 
are robust and permit us to provide a full description of the PK behavior of an antibiotic agent in 
neonates in terms of estimated average PK parameter, inter-subject and intra-subject variability and 
key factors that influence PK behavior of antibiotics during the first weeks of life. Quantitative 
approaches such as pharmacometric modeling and simulation can be used as prior information in 
computer simulation to describe, explain, and investigate different dosing scenarios. Such 
approaches have been applied to analyze the PK of renally eliminated antibiotics such as vancomycin, 
gentamicin, amikacin and meropenem, in order to suggest new dosing recommendations 
[46,47,48,49,50]. 
 
2.3. Case study: fine-tuning of vancomycin dosing 
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Vancomycin is the first choice treatment for serious gram-positive infections, especially involving 
methicillin-resistant Staphylococcus aureus (MRSA). This narrow spectrum glycopeptide is almost 
exclusively cleared by glomerular filtration [51]. It is well established that vancomycin dosing in 
children depends on age, body weight and different maturational aspects. Despite multiple clinical 
studies and population PK analyses, there is still no consistent and validated dosing recommendation 
for vancomycin in neonates [52,53,54,55]. Capparelli et al. developed a population PK model on a 
large population, including 374 preterm and term neonates and young infants less than 2 years of 
age [46]. The authors described organ growth, ante- and post- natal maturation and influence of 
altered renal function on clearance, by incorporating the combination of weight, GA, PNA and serum 
creatinine. They validated their model in a set of 67 neonates, and designed a creatinine-based 
dosing guideline for infants < 60 days (Table 2). The dosing regimen was based only on serum 
creatinine, since it can also reflect both growth and maturational changes [56]. They showed a 
significant improvement, in term of achieving trough levels between 5-10 mcg/mL, compared to 
published guidelines (Neofax), with a percentage of target attainment from 25% to 70%. More recent 
population PK models have been developed, but maturation processes did not include ante-natal 
maturation (use of PNA alone) or did not differentiate ante- and post- natal maturation (use of PMA) 
[47,57,58,59,60]. 
  
3. The PK-PD implications and current challenges in antibiotic use in 
neonates  
 
Pharmacodynamic parameters relate the PK factors to the ability of the antibiotics to kill 
(‘bactericidal’) or inhibit the growth (‘bacteriostatic’) of the infectious agents. The bactericidal 
antibiotics are overall effective in neonatal infections resulting in different targets and dosing 
regimens. Thus, aminoglycosides have a concentration-dependent kill characteristic where effect is 
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primarily determined by the ratio of antibacterial peak concentration over minimum inhibitory 
concentration (PEAK/MIC, Fig. 1), while β-lactam antibiotics have a time-dependent kill characteristic 
with the time for which the drug serum concentration remains above MIC (T>MIC, Fig. 2) as an 
optimal predictor of their efficacy [61]. For time-dependent killing antibiotics with moderate 
persisting killing (e.g. vancomycin), the ratio of the 24-hour area under the concentration (AUC) vs. 
MIC and time curve is the best predictor for its effectiveness.  
While knowledge about the impact of developmental changes on drug PK is increasing, information 
regarding ontogeny on drug effects (PD) is still limited [2]. Differences in neonatal physiology can 
affect PD and may result in variability in drug efficacy or toxicity. Age-related developmental changes 
in the functionality or expression of receptors and differences in disease status may alter the 
pharmacological response to drugs [62]. However, this variability can only be considered once the PK 
aspects have been taken into account. Furthermore, extrapolating drug efficacy from adult data to 
the pediatric population, including neonatal, can streamline drug development only when similar 
disease progression as well as response to the treatment can be assumed [63]. Immaturity may result 
in an altered risk of drug toxicity, even a decreased risk. For example, neonates appear to be less 
susceptible to aminoglycosides renal toxicity compared to children and adults. This PD characteristic 
may be explained by a reduced intracellular accumulation of these compounds in the tubular 
epithelial cells of the renal cortex in neonates [64]. More research, especially on PD of antibiotics in 
the neonatal period and the subsequent clinical implications, is needed. Based on the authors’ 
experience this section addresses the burning challenges faced by clinical pharmacologists, such as 
the impact of kidney function and relevance of therapeutic drug monitoring, to assure optimal use of 
antibiotics in neonates. 
3.1. Kidney function and its impact on PK behavior of antibiotics in neonates 
Nephrogenesis starts at week 5–6 of gestation and is completed around week 34-35. The glomerular 
filtration rate (GFR) in full term neonates is 35 % of adult values, with a rapid increase in GFR during 
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the first 2 weeks of life, reaching adult values by the end of the first year of life. Premature infants 
have similar maturational trends, but with a slower initial GFR rise. Both active tubular secretion and 
reabsorption are also immature at birth (20-30 % of adult reference values) only to reach adult 
values in the second part of infancy or beyond [65,66]. As a consequence of immature kidney 
function neonates may develop an accumulation of antibacterial agents that are excreted via the 
kidneys, with a decrease in plasma clearance and prolonged half-life. Therefore, it is important to 
have valid biomarkers of kidney function, and to consider an increase of drug dosage interval and/or 
reduce maintenance dose in this vulnerable group of patients. Clinical characteristics like weight, 
gestational age, post-menstrual age, co-administration of ibuprofen or perinatal asphyxia hereby 
perform better when compared to single creatinine measurements [26]. Most neonatal 
pharmacologists are aware of this and may adjust the dosage of antibiotics accordingly.  
However and more recently, some patients - including pediatric patients - have been documented to 
display ‘paradoxically’ increased clearance of antibacterial agents, so-called glomerular 
hyperfiltration related to their disease state [67,68]. Unfortunately, this aspect has not yet been 
sufficiently explored in early infancy. In general, glomerular hyperfiltration means that the renal 
clearance of antibiotics is beyond the anticipated physiological range. Accurately defining this is 
difficult, and one of the most sensible definitions is a GFR >10% higher than the normal limits [67]. 
Glomerular hyperfiltration has been documented for beta lactams in adult patients with sepsis, 
resulting in slower eradication of the infection or even introducing resistance [69,70,71]. The 
pathophysiological mechanism responsible for glomerular hyperfiltration in sepsis is not entirely 
clear, but could involve altered renal blood flow. In animal studies, renal blood flow has been shown 
to increase in parallel with cardiac output in early sepsis, while it is diminished in a later phase of 
sepsis, resulting in decreased creatinine clearance [72]. These data confirm that in critically ill 
patients renal clearance might be increased in the acute phase, with significant clinical implications 
at the start of antibacterial treatment. To the best of our knowledge, there are no data on glomerular 
hyperfiltration in the critically ill neonates, but we might certainly expect rapid renal changes during 
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neonatal infections. Since the presence of a weak correlation between the dose administered and 
the concentration reached is one of the circumstances to consider TDM, the variability in renal 
clearance is an argument in support of TDM in neonates.  
 
3.2. Therapeutic drug monitoring of antibiotics in neonates: wasted blood or justified practice? 
Current data suggest that the greatest benefit of TDM can be expected within targeted or special 
subpopulations: those at the extremes of age, those with severely impaired kidney function, and 
those using specific drugs, such as immunosuppressive, antineoplastic or anticonvulsant agents. 
Consequently, neonates fit into this, but experiencing some specific issues of neonatal samples, such 
as low volume, plasma protein content or hyperbilirubinemia. In addition, other issues - including 
non PK – make accurate dosing and monitoring more difficult in neonates. There is often not an 
appreciation of the substantial variability in the rate of drug delivery from the intravenous line in 
neonates, resulting in difficulties in accurately determining the drug PK-PD relationship [14]. On the 
other hand, when the appropriateness of TDM for a particular drug is considered, anticipated 
quantitative relationship between concentration and effects, a narrow therapeutic index and/or 
significant consequences of therapeutic failure are all in favor of using TDM. Furthermore, routine 
TDM is only rational when there is a sufficiently precise and accurate analytical technique, as well as 
well knowledge concerning the PK of the drug and relevant covariates in the specific patient 
population (e.g. weight, age, comorbidity).  
Neonates, with rapid maturational changes, benefit from TDM for commonly used drugs, but mostly 
for aminoglycosides and glycopeptides [59,73]. The inconsistency of dosing guidelines for achieving 
therapeutic serum concentrations using empiric dosing regimens underlines the importance of 
appropriate TDM in neonates. Large inter-individual differences in PK parameters secondary to 
gestational age, co-medication and predictive performance of initial empiric therapy might be 
improved by TDM. However, even when it is implemented, any measurement needs to be integrated 
into the clinical setting of the individual patient. Thus, some relevant issues related to the validated 
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target range and time of sampling may occur. For many drugs, target concentrations are not clearly 
defined in children, but only based on data provided in adults. The antibacterial target range 
validated in adults is used in children, including neonates, although additional data are needed to 
validate that these bacteriological targets are associated with efficacy in neonatal infections. TDM 
sampling for aminoglycosides is traditionally performed at steady state, around the fourth dose. For 
neonates, this may be impractical, since neonatal antimicrobial therapy is often empiric and may be 
discontinued after 72 hours in case of negative blood cultures. Early sampling with subsequent 
Bayesian approaches may be a possible alternative; however this needs to be further evaluated. 
Kadambari et al. demonstrated considerable variation amongst gentamicin monitoring protocols in 
different neonatal units in the UK, with no clear justification [74]. A dosing interval of 24 to 48 hours 
is usually recommended because of reduced clearance and prolonged half-life in neonates. The 
similar conclusion was reached for vancomycin, where the samples were also taken at different 
points during treatment. Most NICUs take samples around the third dose. The peak serum 
vancomycin concentrations have not been consistently associated with efficacy or toxicity in 
neonates, therefore routine sampling of peak serum concentrations may not be necessary. Instead, a 
shift towards taking only routine trough serum concentrations provides optimal efficacy regarding 
TDM in neonates receiving vancomycin [75]. Furthermore, the bioanalytical assays validated to 
measure antibacterial concentrations in neonates may differ. Recently, in a single NICU center we 
have confirmed the relevance of vancomycin bio-assays, and particularly target values may be 
substantially different between assays [76,77]. Such studies strongly suggest that dosage 
individualization and monitoring should not only consider clinical characteristics, but should also be 
tailored to the method of drug quantification. In conjunction with quantitative pharmacology 
approaches and appropriate clinical interpretation, TDM is a valuable tool in NICU. 
 
4. Conclusion 
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Due to highly dynamic period of neonatal development, many covariates such as clinical 
characteristics influence PK in neonates, resulting in large between- and within-patient variability 
both in drug disposition and effects. A quantitative approach, such as pharmacometric modeling and 
simulation, has been shown to be a relevant tool to evaluate and optimize drug dosing regimens, as 
covariates, explaining inter-individual PK variability, may be integrated in a new dosing 
recommendation. Based on this strategy, PK knowledge and dosing recommendations in neonates 
have been significantly improved over the last decades.  
Models that can integrate the time courses of dose-concentration relationships and quantification of 
variability provide a scientific basis for optimizing antibiotics dosing in neonates. However, they are 
not routinely used by practicing neonatologists and pediatricians. For this reason simple bed side 
decision tools are developed to support clinicians in individualizing and optimizing dosing of 
antibiotics in neonates, such as the EzeCHiel platform [http://www.ezechiel.ch/].  
 
5. Expert Opinion  
 
Antibiotics are the class of medicines most frequently prescribed in neonates due to the high 
morbidity and mortality of infectious diseases in preterm and term neonates. Early antibiotic therapy 
and effective dosing are essential to provide optimal response and limit the spread of resistance [4]. 
Applied pharmacokinetics is an opportunity as well as a challenge for optimal use of antibiotics in 
neonates.  In Figure 3, we demonstrate the progress of quantitative clinical pharmacology practice 
over time: from simple and very often inaccurate dosing regimens, through complex dosing and 
model-based antibacterial therapy, to integrated and balanced PK/PD knowledge with an 
individualized approach [76,78,79,80,81].  
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 Pharmacokinetics (PK) of antibiotics has been analyzed for years with classical non-compartmental 
analyses. This simple approach is used to calculate PK parameters such as half-life or area under the 
serum concentration vs. time curve, which reflects total drug exposure. However, such non-
compartmental PK analyses are highly dependent on PK sampling schedules and require consistent 
PK sampling in all study subjects. In contrast, pharmacometric models are built using compartments, 
representing kinetic concepts that do not necessarily represent any particular region of the body, 
linked to each other via rate constants. Individual factors, called covariates in modeling, are 
integrated in such approaches to explain inter-individual pharmacokinetic variability.  Quantitative 
clinical pharmacology approaches, such as pharmacometric modeling and simulation, permit us in 
the future to provide a full description of the PK behavior of antibiotic agents in neonates in terms of 
population average PK parameter, inter-subject and intra-subject variability, and key factors that 
influence PK behavior of antibiotics during the neonatal period. Such pharmacometric approaches 
have been already applied to characterize PK behavior of renally eliminated antibiotics, such as 
vancomycin, gentamicin, amikacin and meropenem, in order to suggest new dosing 
recommendations [46,47,48,49,50]. Furthermore, characterization of relationships between PK and 
PD of antibiotics in neonates is essential to optimize treatment strategies in neonates. Ramos-Marti 
et al. used pharmacometric approaches to investigate optimal dosing of vancomycin in neonates by 
bridging data from dynamics in vitro and in vivo experiments to neonates [82]. 
To further individualize and fine-tune dosing strategies of antibiotics in neonates, especially 
compounds with a relatively narrow therapeutic index, TDM approaches are encouraged. Since the 
presence of a weak correlation between the dose administered and the concentration reached is one 
of the circumstances to consider TDM, whereas the variability in renal clearance is another argument 
in support of TDM in neonates. Clinicians should be aware that there is a next step to support the 
clinical decision making based on the clinical characteristics and the TDM measurement. This next 
step is through advanced TDM practice that leverages Bayesian modeling and simulation methods to 
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guide dosing of antibiotics in neonates, based on 4 components: (i) measured drug concentrations, 
(ii) developed population PK models with quantified variability in key PK parameters such as 
clearance and volume of distribution, (ii) identified time-dependent factors that influence key PK 
parameters during the first weeks of life, and (iv) characterized PD behavior and target levels of 
antibiotics in neonates. With such quantitative clinical pharmacology approaches dose 
recommendations can be optimized and individualized, ensuring safe and effective antibiotic therapy 
in neonates.  
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Figure 1 
Aminoglycosides: PEAK/MIC - optimal predictor of their efficacy 
PEAK – antibacterial peak concentration  
MIC – minimum inhibitory concentration 
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Figure 2 
Penicillines: Time above MIC - optimal predictor of their efficacy 
MIC – minimum inhibitory concentration 
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Figure 3 
Progress of quantitative clinical pharmacology practice for safe and effective antibiotic therapy in 
neonates 
TDM – therapeutic drug monitoring 
PK/PD – pharmacokinetics/pharmacodynamics  
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Table 1.   
Clearance of gentamicin, tobramycin and vancomycin from neonates to adults, based on 
bodyweight-dependent exponent model [27] 
 
 
Table 2.  
Vancomycin dosing regimen proposed by Capparelli et al. [46] 
 
 Gentamicin L/h (L/kg/h) Tobramycin L/h (L/kg/h) Vancomycin  L/h (L/kg/h) 
Neonate (4 kg) 0.21 (0.05) 0.28 (0.07) 0.39 (0.097) 
Infant (10 kg) 0.65 (0.065) 0.90 (0.09) 1.55 (0.155) 
Child (20 kg) 1.38 (0.069) 1.84 (0.092) 2.56 (0.128) 
Adult (60 kg) 4.00 (0.067) 5.34 (0.089) 7.43 (0.124) 
Creatinine (mg/dL) Dose (mg/kg) Dosing interval (h) 
≥ 1.7 15 48 
1.3 – 1.6 10 24 
1.0 – 1.2 15 24 
0.7 - 0.9 20 24 
≤ 0.6 15 12 
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